The abstract is read at the publisher; the summary is JClub's.
In Finnish children with aspartylglucosaminuria homozygous for the Finnish major mutation, Cystadane (betaine) reduced urine glycoasparagines by 68.6% ± 10.8% over 48 months.
- Why it matters: The trial addresses the need for a safe, effective pharmacological chaperone therapy for aspartylglucosaminuria, which features progressive cognitive decline and has limited treatment options.
- What they did: In an investigator-initiated, open-label phase Ib/II study (recruited 25, analyzed 21; ages 3–17), oral Cystadane was evaluated for safety and efficacy, with urine glycoasparagines quantified by liquid chromatography/mass spectrometry and normalized to urine creatinine.
- The result: The primary endpoint was met because urine glycoasparagines were significantly reduced (p = 0.000), and the treatment was reported as safe, supporting further larger and longer studies to assess disease progression.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.